Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Autolus Therapeutics (Nasdaq: AUTL), a biopharmaceutical company focused on programmed T cell therapies, has granted stock options to 60 employees under its 2025 Inducement Plan. The compensation committee approved options to purchase 360,550 shares at an exercise price of $2.47 per share, matching the July 9, 2025 closing price.
The options have a 10-year term with a four-year vesting schedule: 25% vests after one year, followed by monthly vesting over 36 months. These grants were made as inducement awards in accordance with Nasdaq Listing Rule 5635(c)(4).
Autolus Therapeutics (Nasdaq: AUTL), un'azienda biofarmaceutica specializzata in terapie con cellule T programmate, ha concesso opzioni su azioni a 60 dipendenti nell'ambito del suo Piano di Incentivazione 2025. Il comitato per la remunerazione ha approvato opzioni per l'acquisto di 360.550 azioni a un prezzo di esercizio di 2,47 $ per azione, corrispondente al prezzo di chiusura del 9 luglio 2025.
Le opzioni hanno una durata di 10 anni con un piano di maturazione di quattro anni: il 25% matura dopo un anno, seguito da un maturazione mensile per i successivi 36 mesi. Questi premi sono stati concessi come incentivi in conformit脿 alla Regola 5635(c)(4) del Nasdaq.
Autolus Therapeutics (Nasdaq: AUTL), una compa帽铆a biofarmac茅utica centrada en terapias con c茅lulas T programadas, ha otorgado opciones sobre acciones a 60 empleados bajo su Plan de Incentivos 2025. El comit茅 de compensaci贸n aprob贸 opciones para comprar 360,550 acciones a un precio de ejercicio de $2.47 por acci贸n, igualando el precio de cierre del 9 de julio de 2025.
Las opciones tienen un plazo de 10 a帽os con un calendario de adquisici贸n de derechos de cuatro a帽os: el 25 % se adquiere despu茅s de un a帽o, seguido de una adquisici贸n mensual durante 36 meses. Estas concesiones se otorgaron como premios inducidos conforme a la Regla 5635(c)(4) de Nasdaq.
Autolus Therapeutics (雮橃姢雼�: AUTL)電� 頂勲攴鸽灗頇旊悳 T 靹疙彫 旃橂鞐� 欷戩爯鞚� 霊� 靸濍獏瓿淀暀 須岇偓搿�, 2025雲� 鞙犾澑 瓿勴殟鞐� 霐半澕 60氇呾潣 歆侅洂鞐愱矊 欤检嫕 鞓奠厴鞚� 攵�鞐枅鞀惦媹雼�. 氤挫儊 鞙勳洂須岆姅 2025雲� 7鞗� 9鞚� 膦呹皜鞕� 霃欖澕頃� 欤茧嫻 $2.47鞚� 頄夓偓 臧�瓴╈溂搿� 360,550欤�毳� 毵れ垬頃� 靾� 鞛堧姅 鞓奠厴鞚� 鞀轨澑頄堨姷雼堧嫟.
鞓奠厴鞚赌 10雲� 毵岅赴鞚措┌ 4雲� 臧� 甓岆Μ 旆摑 鞚检爼鞚� 鞛堨姷雼堧嫟: 1雲� 頉� 25%臧� 旆摑霅橁碃, 鞚错泟 36臧滌洈 霃欖晥 毵れ洈 甓岆Μ臧� 旆摑霅╇媹雼�. 鞚� 攵�鞐姅 雮橃姢雼� 靸侅灔 攴滌箼 5635(c)(4)鞐� 霐半澕 鞙犾澑 氤挫儊鞙茧 鞚措（鞏挫鞀惦媹雼�.
Autolus Therapeutics (Nasdaq : AUTL), une soci茅t茅 biopharmaceutique sp茅cialis茅e dans les th茅rapies par cellules T programm茅es, a accord茅 des options d'achat d'actions 脿 60 employ茅s dans le cadre de son Plan d'Incitation 2025. Le comit茅 de r茅mun茅ration a approuv茅 des options pour l'achat de 360 550 actions 脿 un prix d'exercice de 2,47 $ par action, correspondant au cours de cl么ture du 9 juillet 2025.
Les options ont une dur茅e de 10 ans avec un calendrier d'acquisition des droits sur quatre ans : 25 % des droits sont acquis apr猫s un an, suivis d'une acquisition mensuelle sur 36 mois. Ces attributions ont 茅t茅 faites en tant que r茅compenses d'incitation conform茅ment 脿 la r猫gle 5635(c)(4) du Nasdaq.
Autolus Therapeutics (Nasdaq: AUTL), ein biopharmazeutisches Unternehmen mit Schwerpunkt auf programmierten T-Zell-Therapien, hat unter seinem Inducement-Plan 2025 60 Mitarbeitern Aktienoptionen gew盲hrt. Der Verg眉tungsausschuss genehmigte Optionen zum Kauf von 360.550 Aktien zu einem Aus眉bungspreis von 2,47 $ pro Aktie, entsprechend dem Schlusskurs vom 9. Juli 2025.
Die Optionen haben eine 10-j盲hrige Laufzeit mit einem vierj盲hrigen Vesting-Zeitplan: 25 % werden nach einem Jahr f盲llig, gefolgt von monatlichem Vesting 眉ber 36 Monate. Diese Zuteilungen wurden als Anreizpr盲mien gem盲脽 Nasdaq Listing Rule 5635(c)(4) gew盲hrt.
- Stock options align employee interests with shareholders
- Structured vesting schedule helps with employee retention
- Potential future dilution for existing shareholders
LONDON & GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc听(Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 360,550 shares of its common stock to 60 employees pursuant to the Company鈥檚 2025 Inducement Plan. The stock options were granted as an inducement material to the individual becoming an employee of Autolus in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of听
About Autolus Therapeutics plc
Autolus Therapeutics plc听(Nasdaq: AUTL) is an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL庐, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit .
颁辞苍迟补肠迟:听听
Amanda Cray听
Executive Director, Investor Relations & External Communications
+1 617-967-0207听
听
FAQ
How many stock options did Autolus Therapeutics (AUTL) grant in July 2025?
What is the vesting schedule for AUTL's July 2025 inducement stock options?
What is the exercise price for Autolus Therapeutics' July 2025 inducement grants?
How long is the term of AUTL's July 2025 inducement stock options?
